Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Tsakatikas A"'
Autor:
Gianniou N, Giannakopoulou C, Dima E, Kardara M, Katsaounou P, Tsakatikas A, Roussos C, Koulouris N, Rovina N
Publikováno v:
Journal of Asthma and Allergy, Vol Volume 11, Pp 81-88 (2018)
Niki Gianniou,1 Charilena Giannakopoulou,2 Efrossini Dima,2 Matina Kardara,3 Paraskevi Katsaounou,1 Alexandros Tsakatikas,4 Charis Roussos,1–3 Nikolaos Koulouris,2 Nikoletta Rovina2 1Pulmonary and Critical Care Department, Evangelismos Hospital, 21
Externí odkaz:
https://doaj.org/article/6fe03f70a8af43909b21fce6618731fe
Autor:
Papageorgiou Sotirios, Anthi Bouchla, Konstantinos Gkontopoulos, Thomas Thomopoulos, Constantinos Loukari, Christina Apostolopoulou, Pinelopi Vryttia, Artemis Zormpa, Sergios Tsakatikas, Vasiliki Pappa
Publikováno v:
HemaSphere, Vol 7, p e33926c2 (2023)
Externí odkaz:
https://doaj.org/article/2dd220df10104afbaee514aef94e646a
Publikováno v:
Cancer Management and Research, Vol Volume 14, Pp 1043-1061 (2022)
Christo Kole,1 Nikolaos Charalampakis,2 Sergios Tsakatikas,2 Maximos Frountzas,3 Konstantinos Apostolou,1 Dimitrios Schizas1 1First Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, 115 27, Greece
Externí odkaz:
https://doaj.org/article/e55e5787a5304041bd20918c358e4dff
Publikováno v:
In Critical Reviews in Oncology / Hematology October 2021 166
Autor:
Georgios I. Papageorgiou, Evangelos Fergadis, Nikos Skouteris, Evridiki Christakos, Sergios A. Tsakatikas, Evangelos Lianos, Christos Kosmas
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Poly-ADP ribose polymerase (PARP) inhibitors are constantly increasing in their indications for use as anti-cancer treatment in various neoplasms, the majority of which are linked with BRCA deficiency. Preclinical data support the investigation of PA
Externí odkaz:
https://doaj.org/article/d0462d14688f4ca3bc41ba28ea0ba502
Autor:
Gianniou, Niki, Katsaounou, Paraskevi, Dima, Efrossini, Giannakopoulou, Chariklia-Eleni, Kardara, Matina, Saltagianni, Vassiliki, Trigidou, Rodoula, Kokkini, Aggeliki, Bakakos, Petros, Markozannes, Evangelos, Litsiou, Eleni, Tsakatikas, Alexandros, Papadopoulos, Christos, Roussos, Charis, Koulouris, Nikolaos, Rovina, Nikoletta
Publikováno v:
In Respiratory Medicine September 2016 118:7-14
Autor:
Pappa, Vasiliki, Vaiopoulos, Aristeidis, Lampadaki, Kyriaki, Koumourtzis, Marios, Fanouraki, Stella, Zis, Panagiotis, Velonakis, Georgios, Thomopoulos, Thomas, Tsakatikas, Sergios, Lakiotaki, Eleftheria, Korkolopoulou, Pinelopi, Papadavid, Evangelia
Publikováno v:
In European Journal of Cancer September 2023 190 Supplement 1
Autor:
Evanthia, Letsiou, Sergios, Tsakatikas, George, Vakis, Konstantinos, Tsapakidis, Nikolaos, Charalampakis, Alexandros, Diamantis, Antigoni, Poultsidi, Dimosthenis, Michelakis, Eelco, de Bree, Davide, Mauri, Nikolaos, Tsoukalas, Chrysostomos, Antoniades, Maria, Tolia
Publikováno v:
Reviews on Recent Clinical Trials. 17:73-85
Introduction:Women undergoing mastectomy choose to pursue breast reconstruction (BR) in order to reduce their body image distress.Adjuvant chest wall irradiation is associated with a negative cosmetic outcome. The aim of our review was to identify th
Autor:
Maria Tolia, Rodanthi Fioretzaki, Dimitrios Schizas, Christo Kole, Stylianos Kykalos, Sergios Tsakatikas, Georgios I Papageorgiou, Nikolaos Charalampakis
Publikováno v:
Immunotherapy. 13:1113-1134
Cholangiocarcinoma (CCA) is a rare malignancy with generally dismal prognosis. Immunotherapy has revolutionized the management of cancer patients during the last decade, offering durable responses with an acceptable safety profile, but there are stil
Autor:
Michail Vailas, Dimitrios Schizas, Nikolaos Charalampakis, Anna Koumarianou, Maria Tolia, Michalis V. Karamouzis, Marina Tsoli, Nikolaos-Iasonas Kouris, Sergios Tsakatikas, Maria Sotiropoulou, Christo Kole
Publikováno v:
Cancer Immunology, Immunotherapy. 71:761-768
Neuroendocrine neoplasms (NENs) are a group of heterogeneous malignancies, arising from the neuroendocrine system. These neoplasms are divided into two distinct groups, the low-proliferating, well-differentiated neuroendocrine tumors (NETs), and the